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Introduction
Status epilepticus (SE) is essentially an acute, prolonged
epileptic crisis, defined by a continuous seizure that lasts
5 min or more. It is the second-most frequent life-
threatening neurological emergency after stroke and bears
considerable risks of morbidity and mortality [1, 2]. To
prevent potentially dismal complications, recent North
American and European guidelines strongly advocate
timely (immediate to urgent) treatment. At present, the
therapeutic arsenal is subdivided into three lines, con-
sisting of the administration of benzodiazepines (first line
of treatment), of antiseizure drugs (second line of treat-
ment), and of general anesthetics (third line of treatment)
[3, 4]. Despite this relatively simple approach, several
uncertainties are associated with the optimal use of spe-
cific agents and the best sequence of their administration
[2, 5]. Our recommended strategy for treating SE treat-
ment is given in Fig. 1. In subsequent sections of this
article we provide an overview of the most recent clinical
findings corroborating this strategy.
Lines of treatment for SE
First line of treatment
In a large multicenter, randomized controlled pre-hos-
pital trial, Silbergleit et al. compared the efficacy of
intramuscular (IM) midazolam (MDZ, 10 mg) and
intravenous (IV) lorazepam (LZP, 4 mg) therapy in 893
adults and children with convulsive SE [6]. The primary
outcome, namely, seizure termination prior to arrival at
the hospital, was achieved in 73 % and 63 % of those
treated with MDZ and LZP, respectively (p \ 0.001 for
superiority). Need to intubation, recurrent seizures, and
safety outcomes were similar among the two treatment
groups, and failure to set an IV line was identified as the
most likely cause of the difference in the primary
outcome.
These findings clearly support the use of IM MDZ as
the preferred first-line treatment, at least for convulsive
SE, at the doses studied. Whether this approach is supe-
rior to the IV administration of LZP at the 0.1 mg/kg
dose, which is standard in North America [3], is still
unknown.
Second line of treatment
A relatively wide palette of IV antiseizure drugs may be
used at this step, including not only the ‘‘classical’’ ones,
i.e., phenytoin (PHT), valproate (VPA), and phenobarbital
(PB), but also levetiracetam (LEV) and lacosamide
(LCM). A few randomized studies have investigated the
effectiveness of PHT, VPA, and LEV, but all are flawed
by methodological issues (sample size, statistical
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approach, use as first-line treatment, or particular geo-
graphical settings where infectious etiologies clearly
predominate), thereby limiting their generalizability.
Therefore, non-randomized analyses may still prove
informative. In an assessment of 187 adult patients with
any SE form, Alvarez et al. focused on the use of LEV,
PHT, and VPA as second-line treatment (loaded at
20 mg/kg after treatment with benzodiazepines) [7].
These authors found that after adjustment for the most
relevant outcome predictors, LEV failed to control SE
more often than VPA [odds ratio (OR) 2.7; 95 % confi-
dence interval (CI) 1.2–6.1] and that PHT was
intermediately effective [7]. One caveat to their study is
the relatively low dosages of LEV and VPA. A meta-
analysis of 22 studies including more than 700 patients,
which assessed the likelihood of various antiseizure drugs
used in second-line treatment to achieve control of SE,
found VPA to have an efficacy of 75.7 % (95 % CI
63.7–84.8 %), LEV 68.5 % (95 % CI 56.2–78.7 %), PB
73.6 % (95 % CI 58.3–84.8 %), and PHT 50.2 % (95 %
CI 34.2–66.1 %) [8]. However, the heterogeneity of the
source data and the lack of adjustment for outcome pre-
dictors are important limitations to this study. Finally, a
retrospective comparison between PHT and LCM (used
however as a third drug, following treatment with ben-
zodiazepines and LEV) in 46 adults showed that SE was
terminated in 40 % of those administered PHT versus
33 % of those receiving LCM (non-significant differ-
ence), with more side effects in the PHT group [9].
At the present time, these findings seem to support the
prescription of VPA (which is also a wide-spectrum
agent) as the preferred second-line agent. However, a
randomized-control trial in this particular setting is
urgently needed [10].
Third line of treatment and beyond
General anesthetics are prescribed in refractory SE (RSE),
but a randomized trial on 24 adults that was interrupted
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Fig. 1 Flow chart of status epilepticus (SE) treatment, with
standard dosages and administration routes. The middle line
(MDZ, VPA) is preferred; alternatives are indicated on the left
and right side. The first line of treatment (benzodiazepines) is
shown in green boxes; the second line of treatment [intravenous
(IV) antiepileptic compounds] in blue boxes, and the third line of
treatment (IV general anesthetics) in orange and lilac boxes;
additional lines are given in red boxes. In patients with ongoing SE
without severe consciousness impairment, non-sedating antiepi-
leptic agents should be preferred—at least initially—to anesthetic
agents (orange box). PO oral administration, IM intramuscular
injection. Single asterisk Not suitable for some generalized
syndromes (including myoclonic or absence seizures), double
asterisks use in combination with benzodiazepines, but avoid
prolonged use without checking creatine kinase, lactate, and
triglycerides. CLZ clonazepam, ECT electro-convulsive treatment,
LCM lacosamide, LEV levetiracetam, LZP lorazepam, MDZ
midazolam, PGB pregabalin, (P)PHT (phospho-)phenytoin, PRO
propofol, PTB pentobarbital, THP thiopental, rTMS repetitive
transcranial magnetic stimulation, TPM topiramate, VNS vagus
nerve stimulation, VPA valproate
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due to insufficient recruitment (underscoring the diffi-
culties of studying this entity) did not disclose any clear
difference between barbiturates and propofol, apart from
a longer intubation time with the former [11]. When RSE
persists after the first anesthetic course, alternative treat-
ment options are required. A recent reappraisal of studies
on ketamine, an N-methyl-D-aspartate (NMDA) antago-
nist, remind that in terms of pathophysiological
considerations, this drug appears to be very promising in
treating RSE. In a retrospective, multicenter assessment
of 58 adults and children (60 episodes) [12], permanent
RSE control was achieved in seven patients (12 %) likely
due to the administration of ketamine; intriguingly, as
many as four of these patients had postanoxic SE (it is
unclear how many survived). No response was observed
below infusion dosages of 0.9 mg/kg/h or if the ketamine
was introduced into the treatment regimen after more than
8 days since the beginning of SE. In this study, safety
concerns lead to discontinuation of the infusion in four
(7 %) subjects [12]. Another retrospective series on 11
adults reported RSE termination in all patients with ket-
amine, seven of them within 1 week of initiating
ketamine treatment (2 subsequently died); SE lasted less
than 8 days in all patients [13]. There were no side
effects.
The ketogenic diet is well known in pediatric epilepsy,
but its use in adult SE also appears promising. A multi-
center retrospective review of ten patients (7 with
encephalitis) showed that despite a very long RSE dura-
tion (up to 2 months), acidosis was reached in nine
patients, with SE ceasing in all of these latter patients at a
median of 3 days thereafter. Two patients died at
6 months [14]. Although potentially flawed by some
selection and information bias due to the study design,
these observations corroborate the efficacy of both the
relatively early use of ketamine in RSE and the ketogenic
diet in adults in the intensive care unit (ICU).
Specific prognostic role of antiepileptic treatment
While endotracheal intubation would seem to be clearly
indicated in patients with ongoing convulsive RSE, there
are no clear data on subjects with RSE forms not
accompanied by profound consciousness disturbance;
moreover, mechanical ventilation and ICU immobiliza-
tion are related to potential important medical
complications. This lack of data illustrates the daunting
tasks faced by the treating physician: to optimize treat-
ment effectiveness and achieve a balance between the
desired efficacy (SE control) and minimal side effects
[15]. The appropriateness of pharmacological SE treat-
ment, quantified according to existing international
recommendations, does not seem to play any significant
prognostic role after adjustment for underlying etiology,
age, SE severity, and medical comorbidities [16]. More-
over, two recent retrospective studies suggest an
association between the use of anesthetics and a risk of
mortality {OR 5.6, 95 %CI 2.3–13.8 in 126 patients [17];
relative risk 2.9, 95 % CI 1.5–5.7 in 171 patients [18]},
after attempting to adjust for relevant outcome predictors.
The considerations mentioned here challenge the
practice of proceeding automatically to endotracheal
intubation in every case of RSE. We suggest that it seems
reasonable, in patients with some preserved conscious-
ness, to attempt additional non-sedating agents before
considering the use of general anesthesia. The special
case of the patient in absence SE virtually never requires
intubation. In all situations, the active search for and the
treatment of the underlying etiology represent an impor-
tant mainstay in the treatment of SE [1].
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